Galectin Therapeutics (GALT) Earnings Date, Estimates & Call Transcripts $4.25 +0.27 (+6.78%) Closing price 04:00 PM EasternExtended Trading$4.14 -0.11 (-2.47%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Galectin Therapeutics Earnings Summary Galectin Therapeutics posted Q2 2025 earnings on August 14, 2025, reporting an EPS of -$0.12, which beat analysts' consensus estimates of -$0.16 by $0.04. With a trailing EPS of -$0.64, Galectin Therapeutics' earnings are expected to decrease next year, from ($0.73) to ($0.92) per share. Upcoming Q3 Earnings DateNov. 13Before Market OpensEstimatedConsensus EPS (Aug. 14) -$0.16 Actual EPS (Aug. 14) -$0.12 Beat By $0.04 Q2 2025 Earnings ResourcesQ2 2025 Earnings Report Quarterly Report (10-Q) Press Release (8-K)GALT Upcoming EarningsGalectin Therapeutics' next earnings date is estimated for Thursday, November 13, 2025, based on past reporting schedules. Powered by Get Galectin Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Galectin Therapeutics and other key companies, straight to your inbox. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Estimated and Actual Earnings DataGALT Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter. Galectin Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$0.24-$0.24-$0.24Q2 20251-$0.16-$0.16-$0.16Q3 20251-$0.11-$0.11-$0.11Q4 20251-$0.10-$0.10-$0.10 Galectin Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 11/13/2025(Estimated)--------8/14/2025Q2 2025-$0.16-$0.12+$0.04-$0.12--5/15/2025Q1 2025-$0.20-$0.15+$0.05-$0.15--3/31/2025Q4 2024-$0.16-$0.19 -$0.03-$0.19--8/13/2024--$0.16-$0.20 -$0.04-$0.20--5/15/2024Q1 2024-$0.16-$0.19 -$0.03-$0.19--3/29/2024Q4 2023--$0.16--$0.16--11/13/2023Q3 2023-$0.16-$0.24 -$0.08-$0.24-- Galectin Therapeutics Earnings - Frequently Asked Questions When is Galectin Therapeutics' earnings date? Galectin Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 13th, 2025 based off last year's report dates. Learn more on GALT's earnings history. Did Galectin Therapeutics beat their earnings estimates last quarter? In the previous quarter, Galectin Therapeutics (NASDAQ:GALT) reported ($0.12) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.16) by $0.04. Learn more on analysts' earnings estimate vs. GALT's actual earnings. How much profit does Galectin Therapeutics generate each year? Galectin Therapeutics (NASDAQ:GALT) has a recorded net income of -$47.05 million. GALT has generated -$0.64 earnings per share over the last four quarters. What is Galectin Therapeutics' EPS forecast for next year? Galectin Therapeutics' earnings are expected to decrease from ($0.73) per share to ($0.92) per share in the next year. More Earnings Resources from MarketBeat Related Companies SYRE Earnings PRAX Earnings CRMD Earnings CRON Earnings NUVB Earnings VERV Earnings VALN Earnings MLYS Earnings ATAI Earnings IOVA Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor After Earnings Miss, Walmart Is Still a Top Consumer Staples PlayRoyal Caribbean Earnings Beat Fuels Strong 2025 OutlookDLocal Stock Soars 43% After Earnings Beat and Raised GuidanceGreen Dot's 30% Rally: Turnaround Takes Off on Explosive EarningsElbit Systems Jumps on Record Earnings and a $1.6B ContractBrinker Serves Up Earnings Beat, Sidesteps Cost Pressures This page (NASDAQ:GALT) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galectin Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galectin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access